Companhia Siderúrgica Nacional (SID)

NYQ – Real Time Price. Currency in USD

1.37

0.00 (0.00%)

At close: May 12, 2026, 4:00 PM EDT

1.37

0.00 (0.00%)

After-hours: May 12, 2026, 7:09 PM EDT

07.05.2026

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DeepBiology--TRexBio to Present Late-Breaking Data at SID 2026 Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis.

05.05.2026

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcinoma Tumors WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced the presentation of Phase 2 clinical data highlighting the potential abscopal effects of the Company's novel oncolytic peptide, VP-315 (ruxotemitide), in the treatment of basal cell carcinoma (BCC) at the 2026 Society for Investigative Dermatology (SID) Annual Meeting, taking place from May 13-16, 2026, in Chicago, Illinois.

12.03.2026

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

15.01.2026

Companhia Siderúrgica Nacional (SID) Shareholder/Analyst Call Transcript

14.01.2026

Siderurgica Nacional (SID) Moves to Buy: Rationale Behind the Upgrade

Siderurgica Nacional (SID) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

14.01.2026

What Makes Siderurgica Nacional (SID) a Strong Momentum Stock: Buy Now?

Does Siderurgica Nacional (SID) have what it takes to be a top stock pick for momentum investors? Let's find out.

14.01.2026

Are Investors Undervaluing National Steel (SID) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Videos

No Data

There is no data to display

Press releases

05.05.2026

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Companhia Siderúrgica Nacional (SID)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Companhia Siderúrgica Nacional (SID)

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Companhia Siderúrgica Nacional (SID) Shareholder/Analyst Call Transcript

Siderurgica Nacional (SID) Moves to Buy: Rationale Behind the Upgrade

What Makes Siderurgica Nacional (SID) a Strong Momentum Stock: Buy Now?

Are Investors Undervaluing National Steel (SID) Right Now?

Videos

No Data

Press releases

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Companhia Siderúrgica Nacional (SID) Shareholder/Analyst Call Transcript

Siderurgica Nacional (SID) Moves to Buy: Rationale Behind the Upgrade

What Makes Siderurgica Nacional (SID) a Strong Momentum Stock: Buy Now?

Are Investors Undervaluing National Steel (SID) Right Now?

Videos

No Data

Press releases

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Search stocks

Companhia Siderúrgica Nacional (SID)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Companhia Siderúrgica Nacional (SID)

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Companhia Siderúrgica Nacional (SID) Shareholder/Analyst Call Transcript

Siderurgica Nacional (SID) Moves to Buy: Rationale Behind the Upgrade

What Makes Siderurgica Nacional (SID) a Strong Momentum Stock: Buy Now?

Are Investors Undervaluing National Steel (SID) Right Now?

Videos

No Data

Press releases

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

Companhia Siderúrgica Nacional (SID) Q4 2025 Earnings Call Transcript

Companhia Siderúrgica Nacional (SID) Shareholder/Analyst Call Transcript

Siderurgica Nacional (SID) Moves to Buy: Rationale Behind the Upgrade

What Makes Siderurgica Nacional (SID) a Strong Momentum Stock: Buy Now?

Are Investors Undervaluing National Steel (SID) Right Now?

Videos

No Data

Press releases

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting